Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Tolerability of the Japanese Encephalitis Vaccine IC51. Double Blind, Randomized, Placebo Controlled Phase 3 Study

NCT00605085 is registered in ClinicalTrials.gov with Valneva Austria GmbH as lead sponsor.

NCT NCT00605085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00605085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Tolerability of the Japanese Encephalitis Vaccine IC51. Double Blind, Randomized, Placebo Controlled Phase 3 Study
Lead sponsor
Valneva Austria GmbH
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2005
Completion date
November 30, 2006
Enrollment
2,675 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

japanese encephalitis